KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Quest Diagnostics (DGX) Non-Current Assets (2016 - 2025)

Quest Diagnostics (DGX) has disclosed Non-Current Assets for 17 consecutive years, with $13.8 billion as the latest value for Q4 2025.

  • Quarterly Non-Current Assets rose 0.62% to $13.8 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $55.1 billion through Dec 2025, up 8.47% year-over-year, with the annual reading at $13.8 billion for FY2025, 0.62% up from the prior year.
  • Non-Current Assets hit $13.8 billion in Q4 2025 for Quest Diagnostics, roughly flat from $13.8 billion in the prior quarter.
  • In the past five years, Non-Current Assets ranged from a high of $13.8 billion in Q4 2025 to a low of $10.7 billion in Q2 2021.
  • Historically, Non-Current Assets has averaged $11.9 billion across 5 years, with a median of $11.7 billion in 2023.
  • Biggest five-year swings in Non-Current Assets: fell 0.89% in 2021 and later grew 18.12% in 2024.
  • Year by year, Non-Current Assets stood at $10.9 billion in 2021, then grew by 0.63% to $10.9 billion in 2022, then rose by 6.5% to $11.6 billion in 2023, then rose by 18.12% to $13.8 billion in 2024, then increased by 0.62% to $13.8 billion in 2025.
  • Business Quant data shows Non-Current Assets for DGX at $13.8 billion in Q4 2025, $13.8 billion in Q3 2025, and $13.8 billion in Q2 2025.